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A trypsin-like proteinase which is inhibited by recombinant gp120 and by synthetic peptides of various lengths spanning the conserved sequence 
of the V3 loop has been purified and partially characterized from a U-937 cell membrane xtract. V3 loop peptides behave as competitive inhibitors 
of the enzyme, while gp120 exerts a tight-binding inhibition, reacting in stoichiometric amounts with the proteinase to provide significant inhibition. 
Though the properties of the U-937 membrane proteinase towards gp120 and synthetic peptides of the V3 loop resemble those of the Molt-4 T-cell 
tryptase TL2, these two proteinases differ by their physicochemical properties and their susceptibility to other inhibitors of serine proteinases. These 
results give support to the concept of a membrane-associated proteinase as a complementary or alternative receptor to the CD4, for allowing virus 
to enter host cells and thus spreading HIV infection. 
HIVl; gpl20 V3 loop; Protemase; Proteinase inhibitor 
1. INTRODUCTION 
HIV infection is mediated by an initial interaction 
between the gp120 envelope glycoprotein of the virus 
and the membrane CD4 receptor of target cells [l]. 
However, other cell surface components may play a role 
in the interaction and membrane fusion, as several types 
of cells lacking the CD4 receptor can be infected by 
HIV, while several cell lines expressing the CD4 recep- 
tor are not susceptible to infection [2-61. Accordingly, 
major neutralizing antibodies are not directed against 
the binding region to CD4 [7-91 and do not inhibit 
binding to CD4. [7-91 and do not inhibit binding to 
CD4. These antibodies recognize a region in the V3 loop 
of gp120 that appears to play a fundamental role in 
infection [7,8,10-151. This loop has a conserved frag- 
ment, GPGRAF, resembling the structure of the reac- 
tive site of Kunitz-type inhibitors of serine proteinases 
[ 121. Kido et al. [ 12,161 first suggested that a protease 
receptor might interact with this region of the V3 loop. 
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They demonstrated the presence of a membrane-associ- 
ated serine proteinase at the surface of Molt-4 T-cells, 
that was inhibited by gp120 through interaction with its 
V3 loop domain [l&18]. However, several ines of evi- 
dence suggest hat HIV interacts with monocytes and 
T-cells differently [19], addressing the question of the 
occurrence of this interaction in monocytes, and as a 
general mechanism in HIV infection. 
Mononuclear phagocytes are important vectors for 
the spread of HIV infection, since they are target cells 
for the virus and regulatory cells carying the virus and 
controlling its dissemination [19-211. This study shows 
that a membrane-associated proteinase is present in the 
U-937 promonocytic cell lines [22]. This enzyme could 
interact with viral glycoproteins through the V3 loop of 
gp120, thus explaining the importance of this region in 
monocyte infection. 
2. MATERIAL AND METHODS 
2.1. Purl$cation of membrane-associated proteinase from V-937 mon- 
ocyle 
A human promonocytic line (U-937) [22] was cultured in RPMI- 
1640 medium (Gibco) supplemented with 10% foetal calf serum, pen- 
icillin G (100 U/ml), streptomycin (100 &ml) and amphotericin B 
(0.25 &ml) (Gibco) at 37°C with 5% CO,. About 10” cells were 
washed twice with PBS (0.01 M sodium phosphate buffer pH 7.4 
containing 0.15 M NaCl) resuspended in relax buffer (10 mM 
piperazme-iV-N’-bis (2-ethane sulfonic acid).HCl pH 6.8, 3.5 mM 
MgCl>. 0.1 M KCl, 1.25 mM ethylenediaminetetraacetic acid) and 
then compressed under N, to 1064 psi for 15 min at 4°C and suddenly 
decompressed. The resulting crude N,-cavitation lysate (about 70 ml) 
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Fig. 1. ~~fi~ation of membmne-ass~iat~ proteinase from mon~yte U-937. Panel a: Eiution from the ~-amino~nz~idin~ag~ose column. 
The bound material corresponding to the hatched area was fractionated on hydroxyapatite (Panel b). The fractions with an activity higher than 
0.005 dOD,iZ/min (hatched area) were pooled and passed twice through a Superose 12 column. Panel c shows the elution profile after the second 
chromatography. Active fractions (hatched area) were pooled, concentrated and kept frozen at -7O’C. 
was centrifuged at 5,000 x g (Beckman 52-21, JA-20 rotor) for 20 min 
at 4°C and the supernatant was used for membrane isolation. The 
supernatant was centrifuged at 100,000 x g for 60 min at 4°C. The 
membrane pellet was suspended in buffer A (0.01 M Bis-Tris-HCl pH 
6.1, 2 M NaCl, 0.05 g/l Thesit), sonicated for 20 s and centrifuged at 
25,000 x g for 20 min at 4°C. The precipitate was re-extracted once 
by sonic&ion in the same buffer and the combined supematants 
(about 10 ml) were used for enzyme isolation. Total serine protemase 
activity was separated from the membrane xtract by affinity chrom- 
atography on ~-aminobenzamidine-agaro~ (Pierce). The affinity col- 
umn (2 ml) was washed with IO volumes of buffer A at 4°C and loaded 
with about 4 ml of supernatant. The unbound material was washed 
out with buffer A and the column was eluted with 10 ml of buffer B 
(0.01 M Bis-Tris-HC1 pH 6.1, 2 M NaCl. 0.15 M benzamidine). All 
eluate fractions were assayed for esterolytic activity using Z-Lys-SBzl 
(Bachem) as a substrate; those with activity were assayed for their 
susceptibility to inhibition by the R13K peptide. The inhibited frac- 
tions were pooled and dialysed against buffer C (5 mM sodium phos- 
phate pH 6.2, 2 M NaCI) for hydroxyapatite chromatography. 
The column of hydroxyapatite (1 x 10 cm; Bio-Rad) was equili- 
brated in buffer C. Unbound material which had most of the estero- 
lytic activity, was coile&ed, pooled and concentrated on a microcon- 
centrator (Centricon 10, Amicon). 
This material was then fractionated twice by high pressure liquid 
chromatography (HPLC) on Superose 12. A 1 ml sample was applied 
to the column and eluted with buffer C at 30 ml/h. The fractions with 
serme-esterase activity were pooled, concentrated on Centricon 
(Amicon) then stored at -70°C until use. The apparent M, of the 
proteinase was determined by SDS-PAGE (125%) according to 
Laemmli [23], using the Phastsystem (Pharmacia). Proteins were 
stained with silver staming 1241. 
2.2. Synthetic peptrdes 
Peptides SP88226 (TRKSIRIQRGPGRAFVK) and SP89487 
(TRKSIRIQRGP), corresponding to fragments (308-323 and 308- 
318, respectively) of the V3 loop sequence of HIV-1 Lai, were obtained 
from the Agence Nationale de Recherches sur le SIDA (ANRS). 
Peptides R13K (RKSIRIQRGPGRK), LlOK (LVGGQVVAGK) 
and R30C (NNTRKSIHIGPGRAFYTTGEIIGDIRQAHC). the lat- 
ter corresponding to the consensus equence reported by LaRosa et 
al. [25], were synthesized by the solid phase method of Merrifield [26] 
using an automated Applied Biosystems 431A peptide synthesizer. 
After cleavage and deprotection, peptides were purified on an Aqua- 
pore RP300 CB column by high pressure liquid chromatography using 
a linear (O--60%) acetonitrile gradient in 0.07% TFA. Their purity was 
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checked by N-amino terminal sequencing on an Applied Biosystems 
477A gas-phase protein apparatus. 
All peptides were assayed kinetically for their capacity to interact 
with the purified membrane proteinase. 
2.3. Kinetzc assays 
Serine-protease activity was measured throughout purification 
using the chromogenic thiobenzylester substrate Z-Lys-SBzl[27]. A 15 
mM stock solution was prepared in dimethylformamide. Enzyme ac- 
tivity was assayed in 0.10 M Tris-HCl buffer pH 8.2.0.35 mM DTNB. 
Proteinase (0.1 to 10 ~1) was mixed with 80 ~1 activator buffer (final 
volume) at 25°C and the reaction started by adding 2 ,ui or 5 ~1 
substrate (respectively 370pM or 940pM final). The rate of hydrolysis 
was calculated by substracting the non-enzymatic rate of absorbance 
increase at 412 nm for the enzyme-catalyzed rate; an extinction coeffi- 
cient change of 13.600 M-‘cm-’ was used for the hydrolysis reaction 
1151. 
The kinetic parameters K,,,, V, and k,,,lK,,, were determined by 
varying the amount of substrate (18 to 940 PM final) and using the 
Hanes linear plot (S/v vs. s) [28]. 
The N-methyl coumarylamide fluorogenic substrates, Pro-Phe- 
Arg-MCA, and Boc-Gln-Gly-Arg-MCA (Bachem), were assayed 
under standardized conditions as previously described [29]. 
Commercial inhibitors, of serine proteinases (STI. Boehringer 
Mannheim; pNPGB. Merck: Aprotinm. Boehringer Mannheim; 
PMSF, Sigma; TLCK, Bachem; Benzamidine, Sigma; Leupeptin, 
Bachem). cysteine proteinases (E64, Bachem) and aspartyl proteinases 
(Pepstatin, Bachem) were assayed by incubating a fixed amount of 
proteinase (2.3 nM final) with a molar excess of inhibitor for 15 min 
at 25°C. Residual activity against Z-Lys-SBzl was determined as be- 
fore. 
SBzl was obtained. The fractions were pooled, ali- 
quoted and kept frozen at -70°C. All these steps were 
carried out in 2 M sodium chloride to preserve the 
serine protease activity extracted from the U-937 cell 
membranes. Under these conditions, full enzymatic ac- 
tivity was recovered after several weeks of storage. After 
concentration, electrophoresis on SDS gels and silver 
staining, the protease eluted from the Superose 12 col- 
umn appeared as a major band of A4, (app) 49,000 (Fig. 
2). 
The purified membrane proteinase was titrated using STI, the con- 
centration of which was first determined with pNPGB-titrated trypsin 
[30]. ST1 was prepared as a 3.5.10-’ M solution in 0.1 M Tris-HCI 
buffer pH 8.2. Purified enzyme (5~1) was incubated for 15 min at 25°C 
with increasing amounts of ST1 before starting the reaction with Z- 
Lys-SBzl. 
Inhibition by peptides of the V3 loop and by gp120 Loi (Transgene) 
was studied by incubating the proteinase (5.7 nM final) for 15 min at 
25°C m the same buffer as before with increasing amounts of either 
peptide or, with gpl20. 
The inhibition constant (K,) for V3 loop peptide R13K, but not for 
gp120 which bound too tightly to the proteinase to obey Michaehan 
kinetics, was calculated by the method of Dixon [31], plotting l/v 
versus I, at two substrate concentrations (0.31 and 0.93 mM). 
The esterase activity of the fractionated material rep- 
resented approximately 8% of the total esterase activity 
initially present in the crude membrane extract (Table 
I) and the purification yield was about 25%. The total 
amount of purified material was determined by active 
site titration with soybean trypsin inhibitor, the most 
potent inhibitor of the protease. A linear titration curve 
was obtained at inhibitor and enzyme concentrations in 
the 10e9 molar range, indicating a K, value below lo-” 
M [32]. The protease is also inhibited by aprotinin, 
PMSF and chloro-methyl ketone, but not by pepstatin 
or E64 (Table II). Hence, it is undoubtly a serine pro- 
tease. Unlike the tryptase TL2 from T-cell membranes 
[16] however, the proteinase was not inhibited by leu- 
peptin (Table II). Kinetic measurements were made 
using the thiobenzylester substrate with trypsin-like 
specificity, Z-Lys-SBzl, which is the most sensitive we 
found for this protease. The kinetic parameters for the 
hydrolysis of Z-Lys-SBzl by the monocyte membrane 
protease are shown in Table III. The protease showed 
a maximal activity at pH 8.2 and was inactive at pH 7 
and below. Calcium chloride (10 mM) did not influence 
the activity. Fluorogenic amide substrates uch as Pro- 
Phe-Arg-MCA and Boc-Gln-Gly-Arg-MCA, the latter 
3. RESULTS Mr 1o-3x 
3.1. Extraction of serine protease activity from cell mem- 
branes 
The soluble material extracted by sonication of the 
membrane pellet from U-937 cells was first fractionated 
by affinity chromatography on immobilized benzamid- 
ine (Fig. la). Only a minor part of the serine proteinase 
activity initially present in the membrane supernatant 
after the centrifugation at 100,000 x g was bound to the 
column under the conditions used. Most of this activity, 
but not that in the unbound material, was inhibited by 
the peptide R13K, which is a conserved sequence of the 
HIV-l V3 loop. Once eluted from the benzamidine col- 
umn, the material with esterolytic activity was fraction- 
ated on hydroxyapatite (Fig. 1 b). The fractions contain- 
ing an esterolytic activity that was inhibited by R13K, 
were further fractionated twice on a Superose 12 col- 
umn (Fig. lc). A single peak that hydrolyzed Z-Lys- 
Fig. 2. Acrylamide (12.5%) gel electrophoresis n the presence of SDS 
of membrane-associated proteinase from monocyte U-937 after the 
last step of purification. Conditions were as described in section 2. 
Serine-proteinase (about 1 ng) was incubated for 3 min with sample 
buffer containing 2-mercaptoethanol prior to electrophoresis. The gel 
was stained with silver staining. Molecular weight markers are indi- 
cated on the left. 
169 
Volume 317, number 1,2 FEBS LETTERS February 1993 
Table I 
Purification of U-937 promonocytic serine proteinase 
Material Volume Activity* 
(ml) (zl OD,,,/min) 
Crude homogenate 6 0.065 
Benzamidine-agarose fractions unbound: 5 0.054 
bound: 3 0.040 
Hydroxyapatite fractions 89.10 4.5 0.023 
Superose 12 fractions 18,19,20 1 0.030 
*Activity in Z-Lys-SBzl esterase assay for whole sample. The rate of 
hydrolysis was calculated after subtracting the non-enzymatic ncrease 
in absorbance at 412 nm from the enzyme catalyzed rate. 
being the preferred substrate of tryptase TL2 [ 161, were 
poorly hydrolysed by the protease as compared to the 
thiobenzylester substrate. 
In a typical experiment, about 10 ,ug purified active 
protease were obtained from a starting homogenate 
containing 10” cells. 
3.2. Inhibition by peptides from the V3 loop 
A synthetic peptide reproducing part of the V3 loop 
sequence of the gp120 of HIV-l was used to identify the 
protease at each stage of the purification procedure 
among proteolytic activities present in U-937 cell mem- 
branes. Only a minor part of the total proteolytic activ- 
ity in cell membranes was inhibited by the so-called 
R13K peptide, showing the relative enrichment in the 
protease of interest during the course of the purification 
(Table I). Whereas the R13K peptide inhibited about 
80% of the esterolytic activity of the purified protease, 
only 10% of the total activity was inhibited in the initial 
extract under the same experimental conditions. 
The inhibition activity of several peptides reproduc- 
ing fragments of the conserved sequence of the V3 loop 
of HIV1 Lai, and a peptide corresponding to the V3 
consensus sequence [25] were tested with a constant 
amount (5.7 nM final) of purified proteinase. All the 
peptides, including the GPGRAF conserved fragment, 
inhibited the U-937 proteinase, though with different 
efficiencies. Peptide SP 89487, which includes only the 
first two residues of the sequence GPGRAF. still inhib- 
ited the protease, demonstrating that all this conserved 
segment is not required for interaction. The consensus 
sequence, which includes the GPGRAF sequence but 
differs by adjacent residues, also inhibited the mem- 
brane proteinase. Variations in the primary structure of 
the V3 loop of gp120 in the vicinity of its GPGRAF 
fragment, would not therefore prevent the viral protein 
from interacting with this proteinase. A K, value of 42 
PM for the interaction of the membrane-associated pro- 
teinase with R13K was calculated from Dixon plots, 
which also indicated that inhibition was competitive 
(not shown). Incubation with an unrelated peptide that 
inhibits cysteine proteinases LlOK [33] had no effect on 
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the U-937 proteinase activity. No peptide cleavage was 
observed during the time of the experiment. However 
R 13K and SP 88226 peptides were cleaved after several 
hours of incubation with proteinase. 
A far more potent inhibition of the U-937 proteinase 
was obtained using recombinant gp120 (Table IV). 
There was significant inhibition at a 1: 1 molar ratio in 
the nanomolar range, making gp120 a tight binding 
inhibitor of the proteinase. This also means that the 
secondary and/or the tertiary structure of gp120 could 
be a major factor in its interaction with a putative en- 
zymic receptor. As reported above for the V3 peptides, 
no proteolytic cleavage of gp120 was observed after 15 
min of incubation with the proteinase, but fragmenta- 
tion of the molecule occurred after overnight incuba- 
tion. 
4. DISCUSSION 
Several ines of evidence suggest hat receptors other 
than the CD4 are involved in the interaction between 
the gpl20 of HIV- 1 and host cells. Neural cells lack this 
receptor, but may still be infected [5] while other brain- 
derived cells which express the receptor remain suscepti- 
ble to infection in the presence of anti-CD4 antibodies 
[2,6,34]. HIV binding to mononuclear phagocytes is 
poorly inhibited by anti-CD4 antibodies, suggesting 
that another receptor is present at the surface of these 
cells [2]. 
It has recently been shown that the infectivity of HIV 
for mononuclear phagocytes may be determined by a 
region of gp120 encompassing the V3 loop, and there- 
fore distinct from the CD4 binding domain [35]. 
Though the nature of the receptor and the mechanism 
of interaction remain unknown, a trypsin-like pro- 
teinase associated with the membrane of Molt-4 T-cells 
has been shown to interact with the V3 loop of gp120 
[ 16.181. This proteinase is therefore a possible addi- 
Table II 
Inhibition spectrum of U-937 promonocytic serine proteinase 
Inhibitor Concentration Inhibition 
(%) 
Soybean trypsin inhibitor 
pNPGB 
Aprotinin 
PMSF 
TLCK 
Benzamidine 
Leupeptin 
Pepstatin 
E&t 
lpM 100 
lpM 36 
lpM 40 
2mM 89 
2mM 31 
2mM 31 
10 mM 0 
10 mM 0 
1 mM 0 
The enzyme (2.3 nM final) was mcubated with inhibitors for 15 min 
at 25°C in 80 ~1 of 0.10 M Tris-HCl. pH 8.2 containing 0.35 mM 
5,5’-dithiobis(nitrobenzoic a id) before starting the reaction with 5 ~1 
of Z-Lys-SBzl (0.37 mM final): dOD,,, was recorded for 5 min. 
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tional or complementary receptor to the CD4. Whether 
this model applies to other cells susceptible to the virus 
is not known. We have demonstrated the presence of 
such a proteinase in membrane xtracts of U-937 mon- 
ocytes. This proteinase interacts with recombinant 
gp120, probably through its V3 loop as deduced from 
its reactivity with peptides panning this sequence of the 
viral envelope glycoprotein. Hence the phenomenon 
first observed for T-cells could also apply to mononu- 
clear phagocytes, in spite of their different mode of 
infection [19,21]. The U-937 monocyte serine proteinase 
activity responsible for this interaction represents about 
10% of the total trypsin-like activity in membranes, as 
in Molt 4 T-cells [16]. As little as 10 pg of proteinase 
may be obtained from 10” cells and the enzyme concen- 
tration in the stock solution is only about lo-’ M which, 
at the moment, prevents from further physicochemical 
or enzymic characterization. Nevertheless, A4, (app), 
esterolytic activity and susceptibility to inhibitors of the 
U-937 membrane proteinase suggest hat it differs from 
tryptase TL2 isolated from Molt-4 T-cell membranes, 
in spite of their similar behaviour towards HIV-l gpl20 
and peptides derived from the V3 loop. 
Apart from the ST1 which was used for active site 
titration, recombinant gp120 appears to be the best in- 
hibitor of the proteinase. Significant inhibition was ob- 
tained under stoichiometric conditions in the nanomo- 
lar range, ranging the viral envelope glycoprotein as a 
tight-binding inhibitor of the proteinase [32]. The initial 
concentration of enzyme was too low however, to allow 
accurate determination of the Ki value under conditions 
of tight binding [36]. The inhibition by peptides span- 
ning the V3 loop of the gp120 shows that at least a part 
of the conserved sequence GPGRAF is involved in inhi- 
bition. Those peptides with inhibitory properties 
obeyed Michaelian kinetics, and a large excess of pep- 
tide over proteinase was required for significant inhibi- 
tion. This differs from the tight-binding properties of 
gp120, and indicates that the conformation of the pep- 
tide in the V3 loop structure is essential for binding [37], 
or that other domains within the gp120 are involved in 
inhibition. We have observed that no significant cleav- 
age of V3 peptides and gp120 occurred during the initial 
stage of the interaction, which leads to strong inhibition 
of the membrane proteinase. Proteolytic cleavage may 
Table III 
Kinetic parameters for U-937 promonocytic serine esterase hydrolysis 
of Z-Lys-SBzl 
Substrate 
;;) @I.&) (3) ($$>) 
Z-Lys-SBzl 175 0.042 7 40.103 
Kinetic constants were calculated from Hanes linear plot [28] using at 
least seven substrate concentrations. 
Table IV 
Inhibition of U-937 promonocytic serine-proteinase activity by gp120 
Lai and by synthetic peptides spanning the V3 loop structure 
Inhibitor Enzyme Concentration E/I Inhibition 
(%) 
gp120 (Lb) 5.7 nM 
3, ,1 
1. ,> 
R13K 3% 
SP88226 3. 
SP89487 3, 
Consensus equence ” 
LlOK 3, 
6.0 nM 0.95 20 
45.8 nM 0.12 35 
91.5 nM 0.06 48 
58.2pM 9.8.105 80 
110.0 PM 5.2.105 60 
62.5pM 9.1.10’ 25 
41.7 FM 1.3.104 30 
40.0 FM 1.4.104 0 
Inhibition was measured with 5.7 nM purified enzyme, 0.94 mM 
Z-Lys-SBzl and 0.35 mM 5-5’-dithiobis(nitrobenzoic a id) in 0.10 M 
Tris-HC1. pH 8.2 as described in the legend of Table II. 
appear however after a longer time of incubation. Such 
a cleavage has been reported as being an essential step 
for virus infection (reviewed in [38]). However, Kido et 
al [18] reported that gp120 was not cleaved upon inter- 
action with tryptase TL2 from T4+ lymphocytes. 
Whether gp120 cleavage is necessary for virus infection 
remains therefore to be demonstrated. Our data support 
the hypothesis that a host cell membrane proteinase 
could interact with an inhibitory site of the V3 loop 
during the process of HIV infection. Such a conforma- 
tional site would not depend on the sequence variability 
of HIV-l strains and would therefore represent a con- 
sensus target to develop inhibitory site-directed anti- 
bodies of therapeutical and/or preventive use. 
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